Therapy Areas: Respiratory
Hydrosome Labs announces promising fermentation breakthrough with ultrafine bubbles
10 September 2025 - Hydrosome Labs, a US biotechnology company focused on ultrafine bubble (UFB) technology, on Tuesday reported new findings from a study with Biocell Energetics, a venture from the U...
Amgen and Kyowa Kirin release rocatinlimab study results in atopic dermatitis
9 September 2025 - US pharmaceutical company Amgen (NASDAQ:AMGN) and Japan-based Kyowa Kirin Co Ltd (TSE:4151) announced on Monday preliminary top-line results from the ASCEND study evaluating rocatin...
Johnson & Johnson's Phase 3 MARIPOSA study shows RYBREVANT and LAZCLUZE prevents acquired resistance versus osimertinib in first-line EGFR-mutated non-small cell lung cancer
8 September 2025 - Johnson & Johnson (NYSE:JNJ), a US-based pharmaceutical and biotechnology company, reported on Saturday that new analyses from the Phase 3 MARIPOSA study shows that first-line t...
Nuvalent presents zidesamtinib ARROS-1 clinical trial data for TKI Pre-treated patients with Advanced ROS1-positive NSCLC at WCLC 2025
8 September 2025 - On Sunday, Nuvalent Inc (Nasdaq: NUVL), a US-based clinical-stage biopharmaceutical company involved in therapies for clinically proven kinase targets in cancer, presented on pivota...
IDEAYA Biosciences and Hengrui Pharma announce IDE849 (SHR-4849) positive Phase 1 data in small cell lung cancer at IASLC 2025 World Conference on Lung Cancer
8 September 2025 - California-based precision medicine oncology company IDEAYA Biosciences Inc (Nasdaq: IDYA) and Hengrui Pharma, a China-based global pharmaceutical company focused on scientific and ...
IDEAYA Biosciences enrols first patient in Phase 1/2 trial of IDE397 and Trodelvy for MTAP-deletion non-small cell lung cancer
4 September 2025 - US-based precision medicine oncology company IDEAYA Biosciences, Inc. (NASDAQ: IDYA) on Thursday announced the enrolment of the first patient with non-small cell lung cancer (NSCLC)...